BeStock  
Stocks › Biotechnology › BNTX

BioNTech BNTX

US equityMarket cap rank #911BiotechnologyInfectious Disease
$80.96 −$0.42 (-0.52%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $81.00 +0.05%
Open$80.82
Prev close$81.38
Day range$80.27 – $82.87
Volume1.71M
Market cap$20.07B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026 · reported in EUR

Revenue€1.29B-15.1% YoY
Operating profit€138.10M-78.9% YoY
Net profit€184.50M+742.9% YoY
Diluted EPS€0.73+708.3% YoY
Free cash flow-€178.30M-124.0% YoY
Operating cash flow-€129.80M

Revenue, last 8 quarters

€1.2BDec '24€182.8MMar '25€260.8MJun '25€1.5BSep '25€907.4MDec '25€118.1MMar '26€105.6MJun '26€1.3BSep '26

Net profit, last 8 quarters

€259.5MDec '24€-415.8MMar '25€-386.6MJun '25€-28.7MSep '25€-305.0MDec '25€-531.9MMar '26€-820.8MJun '26€184.5MSep '26

Diluted EPS by quarter

1.08Dec '24-1.73Mar '25-1.60Jun '25-0.12Sep '25-1.25Dec '25-2.10Mar '26-3.24Jun '260.73Sep '26

Free cash flow by quarter

€-554.4MDec '24€-1.4BMar '25€116.3MJun '25€742.1MSep '25€247.4MDec '25€-499.9MMar '26€-44.9MJun '26€-178.3MSep '26

Annual revenue

€482.3MFY20€19.0BFY21€17.3BFY22€3.8BFY23€2.8BFY24€2.9BFY25

Profitability & balance sheet

Gross margin75.0%
Operating margin-72.7%
Net margin-60.9%
Return on equity-8.1%
Return on assets-7.1%
Return on invested capital-8.0%
Current ratio8.55
Liabilities / assets12.2%
Cash & investments€14.66B
Total debt€312.80M
Net cash (debt)€14.34B

This company reports in its own local currency, not U.S. dollars. Every figure below is labeled with its real currency, not automatically converted.

Income statement

Line item 2026 Q3
(EUR)
2026 Q2
(EUR)
2026 Q1
(EUR)
2025 ANNUAL
(EUR)
2025 Q4
(EUR)
Total Revenue as Reported €1.29B €105.60M €118.10M €2.87B €907.40M
Total Operating Revenue €1.29B €105.60M €118.10M €2.87B €907.40M
Cost of Revenue €103.30M €97.00M €71.40M €641.80M €333.30M
Gross Profit €1.19B €8.60M €46.70M €2.23B €574.10M
Operating Expense €1.05B €947.30M €724.20M €2.87B €854.60M
Selling and Admin Expenses €202.00M €197.80M €150.80M €698.20M €291.70M
-Selling & Marketing Expense €43.30M €40.10M €27.90M €110.00M €49.30M
-General & Admin Expense €158.70M €157.70M €122.90M €588.20M €242.40M
Research & Development €748.10M €551.00M €557.00M €2.10B €505.40M
Other Operating Expenses €97.70M €198.50M €16.40M €65.70M €57.50M
Operating Profit €138.10M -€938.70M -€677.50M -€640.70M -€280.50M
Net Non-Operating Interest Income (Expense) €67.80M €62.70M €109.40M -€12.60M -€5.10M
Non-Operating Interest Income €69.80M €66.40M €120.60M – –
Non-Operating Interest Expense €3.50M €3.50M €11.20M €14.20M –
Total Other Finance Costs -€1.50M €200,000.00 €700,000.00 -€1.60M -€9.30M
Other Income (Expense) €16.10M €17.30M €46.10M -€397.50M €58.20M
Gain on Sale of Security €29.30M €24.40M €46.40M €383.40M €110.30M
Special Income (Charges) -€13.20M -€7.10M -€300,000.00 -€780.90M -€52.10M
-Less:Restructuring and Mergern & Acquisition €0.00 €0.00 €0.00 -€15.00M €0.00
-Less:Other Special Charges €13.50M €7.10M – €789.50M €45.70M
-Less:Write Off -€300,000.00 €0.00 €300,000.00 €6.40M –
Pretax Profit €222.00M -€858.70M -€568.10M -€1.05B -€227.40M
Tax €37.50M -€37.90M -€36.20M €85.30M €77.60M
Net Profit €184.50M -€820.80M -€531.90M -€1.14B -€305.00M
Profit from Continuing Operations €184.50M -€820.80M -€531.90M -€1.14B -€305.00M
Net Income to Parent Company €184.50M -€820.80M -€531.90M -€1.14B -€305.00M
Net Income to Common Stockholders €184.50M -€820.80M -€531.90M -€1.14B -€305.00M
Basic EPS €0.74 -€3.24 -€2.10 -€4.70 -€1.25
Diluted EPS €0.73 -€3.24 -€2.10 -€4.70 -€1.25

Balance sheet

Line item 2026 Q3
(EUR)
2026 Q2
(EUR)
2026 Q1
(EUR)
2025 ANNUAL
(EUR)
2025 Q4
(EUR)
Total Assets €20.17B €20.34B €21.07B €21.99B €21.99B
Total Current Assets €15.67B €15.30B €15.53B €16.15B €16.15B
Cash and Cash Equivalents & Short-Term Investments €14.66B €14.78B €14.64B €14.88B €14.88B
-Cash and Cash Equivalents €10.20B €9.74B €9.94B €7.68B €7.68B
-Short Term Investments €4.46B €5.04B €4.70B €7.20B €7.20B
Receivables €796.00M €245.20M €612.20M €984.90M €984.90M
-Accounts Receivable €666.30M €163.90M €539.20M €924.20M €924.20M
-Taxes Receivable €124.30M €70.90M €64.10M €52.60M €52.60M
-Other Receivables €5.40M €10.40M €8.90M €8.10M €8.10M
Inventory €64.90M €100.60M €103.80M €110.70M €110.70M
Other Current Assets €145.20M €172.70M €176.60M €173.80M €173.80M
Total Non-Current Assets €4.50B €5.05B €5.54B €5.84B €5.84B
Net PPE €1.16B €1.22B €1.32B €1.29B €1.29B
-Gross PPE €1.16B €1.22B €1.32B €1.77B €1.77B
Investments and Advances €1.73B €2.01B €2.28B €2.55B €2.55B
-Available for Sale Securities €1.67B €2.01B €2.28B €2.55B €2.55B
Financial Assets €0.00 – – – –
Goodwill and Other Intangible Assets €1.58B €1.79B €1.92B €1.97B €1.97B
-Goodwill €376.00M €373.30M €370.50M €367.90M €367.90M
-Other Intangible Assets €1.20B €1.42B €1.55B €1.61B €1.61B
Non-Current Deferred Assets €20.00M €15.70M €14.70M €13.50M €13.50M
Other Non-Current Assets €15.00M €10.30M €12.20M €7.30M €7.30M
Total Liabilities €2.46B €2.59B €2.38B €2.76B €2.76B
Total Current Liabilities €1.83B €1.95B €1.77B €2.14B €2.14B
Payables €536.30M €667.90M €506.90M €600.50M €600.50M
-Accounts Payable €523.10M €646.70M €468.80M €534.90M €534.90M
-Total Tax Payable €13.20M €21.20M €38.10M €65.60M €65.60M
Short-Term Debt and Capital Lease Obligation €104.40M €57.20M €56.70M €52.20M €52.20M
-Current Debt €57.40M €57.20M €56.70M €52.20M €52.20M
-Current Capital Lease Obligation €47.00M – €45.90M – –
Current Provisions €244.20M €234.90M €167.00M €145.30M €145.30M
Current Deferred Liabilities €623.60M €742.50M €758.50M €754.90M €754.90M
Other Current Liabilities €324.30M €246.70M €275.90M €589.40M €589.40M
Total Non-Current Liabilities €629.30M €635.90M €611.30M €622.10M €622.10M
Long Term Debt and Capital Lease Obligation €255.40M €258.90M €246.10M €215.20M €215.20M
-Long Term Debt €110.80M €258.90M €246.10M €215.20M €215.20M
-Long Term Capital Lease Obligation €144.60M – €179.50M – –
Derivative Product Liabilities €0.00 – – – –
Non-Current Liabilities €64.60M €58.60M €23.80M €35.50M €35.50M
Non-Current Deferred Liabilities €83.30M €120.90M €140.60M €172.30M €172.30M
Other Non-Current Liabilities €226.00M €197.50M €200.80M €199.10M €199.10M
Total Equity €17.71B €17.76B €18.70B €19.22B €19.22B
Stockholders' Equity €17.71B €17.76B €18.70B €19.22B €19.22B
Capital Stock €259.00M €259.00M €259.00M €259.00M €259.00M
-Common Stock €259.00M €259.00M €259.00M €259.00M €259.00M
Additional Paid-In Capital €2.08B €2.34B €2.47B €2.47B €2.47B
Retained Earnings €16.79B €16.61B €17.43B €17.96B €17.96B
Less: Treasury Stock -€11.10M -€7.80M -€6.10M -€7.70M -€7.70M
Gains/Losses Not Affecting Retained Earnings -€1.41B -€1.44B -€1.45B -€1.46B -€1.46B
-Accumulated Depreciation – – – -€475.50M -€475.50M
Non Current Accounts Receivables – – – €2.00M €2.00M

Cash flow

Line item 2026 Q3
(EUR)
2026 Q2
(EUR)
2026 Q1
(EUR)
2025 ANNUAL
(EUR)
2025 Q4
(EUR)
Operating Cash Flow -€129.80M €10.50M -€421.00M €456.00M €309.50M
Net cash flow from continuing operations -€129.80M €10.50M -€421.00M €456.00M €309.50M
Net Income from Continuing Operations €184.50M -€858.70M -€568.10M -€1.05B -€219.70M
Gain/Loss from Continuing Operations -€3.30M €16.40M €300,000.00 -€19.50M -€54.20M
Depreciation & Depletion & Amortization €332.30M €266.10M €121.30M €382.80M €164.80M
Deferred Tax €37.50M – – – –
Other Non-Cash Items -€89.10M -€80.50M -€105.20M €169.70M €517.20M
Change in Working Capital -€653.20M €593.90M €66.20M €537.80M -€214.50M
-Change in Receivables -€489.10M €366.00M €431.10M €1.08B €78.20M
-Change in Inventory €33.50M €3.20M €7.00M €177.90M €116.20M
-Change in Payables and Accrued Expense -€197.60M €224.70M -€371.90M -€723.80M -€408.90M
Net cash flow from investing €807.70M -€100.10M €2.65B -€2.47B -€2.73B
Net Cash Flow from Continuing Investing Activities €807.70M -€100.10M €2.65B -€2.47B -€2.73B
Net PPE Purchase and Sale -€32.10M -€51.20M -€55.20M -€170.60M -€62.60M
Net Intangibles Purchase and Sale -€14.90M -€800,000.00 -€22.10M -€573.90M €1.10M
Net Business Purchase and Sale -€31.80M €0.00 €0.00 €186.30M €264.80M
Net Investment Purchase and Sale €886.50M -€48.10M €2.73B -€1.91B -€2.93B
Financing Cash Flow -€232.60M -€108.50M €26.40M -€52.90M -€14.30M
Net Cash Flow from Continuing Financing Activities -€232.60M -€108.50M €26.40M -€52.90M -€14.30M
Net Issuance Payments Of Debt €41.70M €20.70M €26.40M -€50.90M -€12.30M
Net Common Stock Issuance -€274.30M -€129.20M – €0.00 €0.00
Ending Cash Balance €10.20B €9.74B €9.94B €7.68B €7.68B
Net Change in Cash €445.30M -€198.10M €2.26B -€2.07B -€2.43B
Beginning Cash Balance €9.74B €9.94B €7.68B €9.76B €10.09B
Effect of Exchange Rate Changes €2.00M -€3.30M -€3.40M -€27.00M €1.40M
Free Cash Flow -€178.30M -€44.90M -€499.90M -€293.00M €247.40M
Net Other Financing Charges – – – -€2.00M –

Discussion

No comments yet — be the first to weigh in on BNTX.

Sign in to join the discussion.

Scroll to Top